Action
- Adaptogenic
- Pronounced anti-fatigue and preventive mental and physical fatigue
- Antioxidant
- Stabilizing cell membranes
- Supports cellular balance of calcium, magnesium, potassium and sodium
- Normalizing the balance of neurotransmitters in the central nervous system
- Detoxifying
- Liver Protectant
- Sleep improver
- Normalizing blood pressure
- Antiatherosclerotic
- Protective Heart
- Antiarrhythmic
- Normalizes blood glucose levels
- Moderate pain reliever for chronic pain
- Anticonvulsant
CardioActiv® Taurine ()
Taurine is a natural metabolic product of sulfur-containing amino acids: cysteine, cysteamine, methionine. Taurine has osmoregulatory and membrane protective properties, has a positive effect on the phospholipid composition of cell membranes, and normalizes the exchange of calcium and potassium ions in cells. Taurine has been shown to have the properties of an inhibitory neurotransmitter; it has an anti-stress effect, can regulate the release of gamma-aminobutyric acid (GABA), adrenaline, prolactin and other hormones, as well as regulate responses to them. By participating in the synthesis of respiratory chain proteins in mitochondria, taurine regulates oxidative processes and exhibits antioxidant properties; affects enzymes, such as cytochromes, involved in the metabolism of various xenobacters.
Taurine improves metabolic processes in the heart, liver and other organs and tissues. In chronic diffuse liver diseases, taurine increases blood flow and reduces the severity of cytolysis.
Treatment with CardioActiv®
Taurine in cardiovascular failure (CVF) leads to a decrease in congestion in the pulmonary and systemic circulation: intracardiac diastolic pressure decreases, myocardial contractility increases (maximum speed of contraction and relaxation, contractility and relaxation indices). The drug moderately reduces blood pressure (BP) in patients with arterial hypertension and has virtually no effect on blood pressure in patients with cardiovascular failure with low blood pressure.
CardioActiv® Taurine reduces side effects that occur with an overdose of cardiac glycosides and blockers of “slow” calcium channels; reduces the hepatotoxicity of antifungal drugs. Increases performance during heavy physical activity.
In case of diabetes mellitus, approximately 2 weeks after starting to take CardioActiv® Taurine, the concentration of glucose in the blood decreases. There was also a significant decrease in the concentration of triglycerides, and to a lesser extent in the concentration of cholesterol, and a decrease in the atherogenicity of plasma lipids. With long-term use of the drug (about 6 months), an improvement in the microcirculatory blood flow of the eye was noted. Taurine improves metabolic processes in the heart, liver and other organs and tissues.
In chronic diffuse liver diseases, taurine increases blood flow and reduces the severity of cytolysis.
Indications
General indications:
- Increasing resistance to great mental, emotional, physical stress and adverse environmental factors.
- Acute and chronic stress.
- Sleep disorders (prolonged falling asleep, interrupted sleep, early awakening).
- Irritability, excess anger and anger.
- Decreased mood.
- Attention deficit and hyperactivity in children.
- Programs for improving the liver and biliary tract.
- Increased weather sensitivity.
- Excess fluid in the body of various origins.
Sports activities:
- Increases the volume of muscle cells.
- To increase endurance, to prevent and correct fatigue.
The cardiovascular system:
- Hypertension.
- Prevention and correction of atherosclerosis.
- Cardiac ischemia.
- Heart arythmy.
- Congestive heart failure.
Liver and bile ducts:
- Biliary dyskinesia.
- Cholelithiasis.
- Stagnation of bile (cholestasis), fatty infiltration (fatty hepatosis).
- Hepatitis and other liver damage of a viral and toxic nature.
- Cirrhosis.
Endocrine system:
- Hypoglycemia.
- Metabolic syndrome.
- Diabetes mellitus type 1 and 2.
Nervous system:
- Tics, muscle cramps.
- Epilepsy.
- Alcoholism (participation in relieving ethanol withdrawal syndrome).
- Encephalopathies, especially those associated with liver damage.
- Increased intracranial pressure, swelling of brain tissue.
Organ of vision:
- Cataract.
- Glaucoma.
Special conditions:
- Rehabilitation after chemotherapy and especially radiotherapy.
Taurine and diabetes
Numerous studies show that the content of taurine in tissues in patients with diabetes is significantly reduced [45]. This may be due to the accumulation of sorbitol in tissues upon activation of the polyol pathway of glucose oxidation under hyperglycemia. On the one hand, this leads to a decrease in the synthesis of taurine in cells, and on the other hand, to a decrease in the activity of glutathione reductase and, consequently, to a decrease in the reduction of oxidized glutathione, which leads to oxidative stress of the cell [46]. Taurine has been shown to reduce sorbitol levels under hyperglycemic conditions, thus exhibiting antioxidant properties.
As is known, the main cause of death in patients with diabetes is coronary heart disease. Endothelial dysfunction, dyslipidemia, and increased platelet aggregation play a key role in its development.
It was found that taurine is able to bind lipid hydroperoxides that disrupt the integrity of the endothelial epithelium, and thus prevent cell apoptosis, as well as the development of endothelial dysfunction [53].
Taurine in the composition of taurocholic bile acids takes an active part in the elimination of cholesterol. Taurine supplementation has been shown to reduce cholesterol levels in rats fed an atherogenic diet [47, 48].
A decrease in taurine content in platelets of patients with diabetes leads to an increase in intracellular Ca2+ in them, since this substance is the most important regulator of intracellular calcium [50-52]. This is accompanied by an increase in platelet aggregation ability and an increase in the risk of thrombosis. The use of taurine in patients with diabetes is accompanied by a decrease in platelet hyperreactivity [49, 53].
The importance of activation of the polyol pathway of glucose oxidation in the genesis of diabetic retinopathy, cataracts, neuro- and nephropathy is well known. Intracellular accumulation of sorbitol leads to the so-called. osmotic and oxidative stress. Thus, it seems quite logical to use taurine as an osmoregulator and antioxidant in order to prevent the progression of diabetic complications.
The course of type 2 diabetes is characterized by progressive insulin deficiency, ultimately leading to the need to transfer patients to insulin replacement therapy. The development of insulin deficiency in type 2 diabetes is associated with the effect of glucotoxicity due to the induction of oxidative stress and apoptosis of pancreatic β-cells [54]. The protective role of taurine was demonstrated in an experiment on isolated islets of Langerhans under conditions of oxidative stress induced by high concentrations of glucose [55] or fatty acids [56].
Taurine is a necessary amino acid for the formation of normal insulin-secreting function of islets during intrauterine development. When studying insulin secretion in newborn rat pups, it was shown that the secretory capabilities of β-cells of rat pups whose mothers received a low-protein diet during pregnancy were significantly reduced compared to controls. At the same time, in rat pups whose mothers received taurine during gestation along with a low-protein diet, insulin secretion did not differ from the control [57].
These data suggest an association between a decrease in taurine levels during pregnancy and the possibility of developing type 2 diabetes in the offspring in the future [58].
One of the main pathogenetic factors in the development of type 2 diabetes is insulin resistance, which progresses with the development of carbohydrate metabolism disorders associated with oxidative stress. During the autoxidation of glucose under conditions of hyperglycemia, excessive formation of diacylglycerol occurs, the main stimulator of protein kinase C (PKC) activity. Activation of PKC leads to disruption of signal transmission through insulin receptors of cells. Taurine inhibits PKC activity by reducing diacylglycerol production. Studying insulin sensitivity in obese rats with spontaneous type 2 diabetes, Y. Nakaya et al. found an increase in insulin sensitivity associated with improved lipid metabolism, a decrease in lipoprotein oxidation and peroxynitrite levels (indirect markers of oxidative stress), which suggests an indirect antioxidant effect of taurine [59].
Method of use
For adults.
In most cases, 1 capsule 2-3 times a day on an empty stomach for 1 month several times a year. In some cases, the dose can be increased to 2 capsules 2-3 times a day.
The metabolic effect of ORTO © TAURINE ERGO manifests itself after 10-14 days of use.
For insomnia, 1-2 capsules 40 minutes before bedtime, or 1-2 capsules between lunch and dinner, and 1-2 capsules at night for 10-30 days in repeated courses.
Before heavy physical activity, take 2-3 capsules once.
For irritability and fatigue, 1-2 capsules per day for 7-14 days.
For excess weight, 1 capsule 3 times a day for a long time.
For metabolic syndrome and diabetes mellitus, 1 capsule 2-3 times a day for 2-6 months.
For liver diseases (chronic hepatitis, cirrhosis, alcohol and other intoxications) 1 capsule 2-3 times a day for a month in repeated courses.
For cardiac arrhythmia and heart failure - 2-3 capsules 3 times in monthly courses.
For children, dosages are reduced by 2-3 times.
Gestational diabetes mellitus
One study examined 72 women, including 43 with a history of gestational diabetes mellitus (GDM), 7 with impaired glucose tolerance (IGT), and 22 with normal glucose tolerance. A glucose tolerance test was performed at 24-28 weeks of pregnancy [24]. Plasma taurine was found to be significantly lower in women with a history of GDM, but not in women with IGT. In addition, plasma taurine levels were inversely related to the area under the glucose curve before pregnancy and the C-peptide/glucose ratio during and after pregnancy (p < 0.05). The relative risk (RR) of impaired glucose metabolism during previous pregnancies (GDM + IGT) increased with decreasing taurine levels and taking into account adjustment for age, body mass index, and history of diabetes (RR = 0.980; p = 0.003). Thus, plasma taurine content may serve as a marker of changes in glucose metabolism in women with GDM.
So, taurine deficiency is observed in various diseases. Currently, we can talk about the important role of taurine as a modulator of many pathophysiological processes in the human body. There is reason to believe that sufficient consumption of taurine and elimination of its deficiency in the body will make it possible to more effectively combat many chronic non-infectious diseases.
CardioActive Taurine tablet 500 mg x60
CardioActive Taurine tablet 500 mg x60, ATX code: C01EB (Other drugs for the treatment of heart diseases) Active substance: taurine Rec.INN registered by WHO
Dosage form
CARDIOACTIVE TAURINE
tab. 500 mg: 40 or 60 pcs.reg. No.: LP-002686 dated 10/29/14 - Valid
Release form, composition and packaging
Tablets are white or almost white, flat-cylindrical, scored and chamfered.
1 tab.
taurine 500 mg
Excipients: povidone - 57 mg, microcrystalline cellulose - 18 mg, croscarmellose sodium - 17.2 mg, calcium stearate - 4.8 mg, colloidal silicon dioxide - 3 mg.
Clinical-pharmacological group: Drug that improves metabolism and energy supply to tissues Pharmaco-therapeutic group: Metabolic agent The scientific information provided is general and cannot be used to make a decision about the possibility of using a specific drug.
, Pharmacological action A sulfur-containing amino acid formed in the body during the conversion of cysteine. Helps improve energy processes. Stimulates reparative and regenerative processes in diseases of a dystrophic nature and/or diseases accompanied by a sharp disturbance in the metabolism of eye tissue. Helps normalize the functions of cell membranes and activate energy metabolic processes. ,
Indications
For oral administration: cardiovascular failure of various etiologies, intoxication with cardiac glycosides, diabetes mellitus type 1 and 2.
For parenteral use: as part of combination drugs, cardiovascular failure (of various etiologies), intoxication with cardiac glycosides.
For use in ophthalmology: dystrophic lesions of the retina, incl. hereditary taperetinal abiotrophies, corneal dystrophy, cataracts (senile, diabetic, traumatic, radiation), as well as corneal injuries (as a stimulator of reparative processes).
ICD-10 codes,
Dosage regimen
The dosage regimen depends on the indications and the dosage form of the drug used.
Side effects Possible: allergic reactions. ,
Contraindications for use: Hypersensitivity to taurine. ,
Special instructions There is evidence of the effectiveness of taurine as a means of reducing intraocular pressure in patients with glaucoma.
